What is Xigduo EMA?
“Xigduo EMA” usually refers to Xigduo, which is an EU/EMA-labeled product (EMA = European Medicines Agency). Xigduo is a brand name for a diabetes medicine that combines two active ingredients.
Which active ingredients are in Xigduo?
Xigduo’s combination therapy is:
- dapagliflozin (an SGLT2 inhibitor)
- metformin (a biguanide)
This combination is used for type 2 diabetes to improve blood sugar control.
What is Xigduo EMA used for (indication)?
Based on how Xigduo is labeled in the EU, it’s used in adults with type 2 diabetes to improve glycemic control, typically:
- when diet and exercise alone do not provide sufficient control, and/or
- when treatment with the individual components is appropriate (dapagliflozin + metformin)
(If you tell me the exact country or the patient population you mean—new diagnosis, add-on therapy, or switching from separate pills—I can narrow this to the most relevant labeling wording.)
What form does Xigduo come in, and how is it taken?
Xigduo is an oral tablet (combination). Typical use in EU labeling is with food or after food to reduce stomach side effects from metformin, while dosing schedules depend on the exact strength tablet and clinician instructions.
Common questions people search alongside “Xigduo EMA”
People often look up:
- side effects (especially genital infections, urinary tract infections, and metformin-related GI effects)
- contraindications (kidney impairment and other situations where metformin or SGLT2 inhibitors aren’t appropriate)
- risk warnings (such as dehydration/low blood pressure with SGLT2 inhibitors and lactic acidosis risk with metformin)
- who should not take it and what monitoring is recommended
If you want, paste the exact EMA wording or the link you’re looking at and I’ll translate it into plain language (indication, dosage, warnings, and eligibility).
Patents/exclusivity research
If you’re asking for patent or exclusivity information for the Xigduo combination, DrugPatentWatch.com is a useful place to check.
You can search there directly: DrugPatentWatch.com
---
Sources
No specific EMA or Xigduo label source was provided in your prompt, so I did not cite an EMA document directly.